ATE551997T1 - Sulfonamid-derivate zur behandlung von diabetes - Google Patents

Sulfonamid-derivate zur behandlung von diabetes

Info

Publication number
ATE551997T1
ATE551997T1 AT04787131T AT04787131T ATE551997T1 AT E551997 T1 ATE551997 T1 AT E551997T1 AT 04787131 T AT04787131 T AT 04787131T AT 04787131 T AT04787131 T AT 04787131T AT E551997 T1 ATE551997 T1 AT E551997T1
Authority
AT
Austria
Prior art keywords
group
sulfonamide
treatment
hydrogen
nitrogen atom
Prior art date
Application number
AT04787131T
Other languages
English (en)
Inventor
Thomas Rueckle
Pierre-Alain Vitte
Jean-Pierre Gotteland
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Application granted granted Critical
Publication of ATE551997T1 publication Critical patent/ATE551997T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04787131T 2003-09-12 2004-09-13 Sulfonamid-derivate zur behandlung von diabetes ATE551997T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03102742 2003-09-12
PCT/EP2004/052143 WO2005025558A1 (en) 2003-09-12 2004-09-13 Sulfonamide derivatives for the treatment of diabetes

Publications (1)

Publication Number Publication Date
ATE551997T1 true ATE551997T1 (de) 2012-04-15

Family

ID=34306923

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04787131T ATE551997T1 (de) 2003-09-12 2004-09-13 Sulfonamid-derivate zur behandlung von diabetes

Country Status (10)

Country Link
US (1) US7705052B2 (de)
EP (1) EP1663193B1 (de)
JP (1) JP4870562B2 (de)
AT (1) ATE551997T1 (de)
AU (1) AU2004271741A1 (de)
CA (1) CA2534312A1 (de)
ES (1) ES2385219T3 (de)
IL (1) IL174251A0 (de)
NO (1) NO20061598L (de)
WO (1) WO2005025558A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE419247T1 (de) * 2001-07-23 2009-01-15 Serono Lab Arylsulfonamidderivate als hemmer c-jun- terminaler kinasen (jnk)
ATE551997T1 (de) 2003-09-12 2012-04-15 Merck Serono Sa Sulfonamid-derivate zur behandlung von diabetes
AU2011265521B9 (en) * 2005-07-15 2014-05-22 Merck Serono Sa JNK inhibitors for the treatment of endometreosis
EA013875B1 (ru) * 2005-08-12 2010-08-30 Сувен Лайф Сайенсиз Лимитед Аминоарильные сульфонамидные производные как функциональные 5-нтлиганды
CN101801375B (zh) 2007-01-25 2014-01-01 韦尔瓦制药有限公司 胰岛素增敏剂和治疗方法
US8225729B2 (en) * 2008-12-16 2012-07-24 Kimberly-Clark Worldwide, Inc. Three-dimensional wiping substrate and method therefor
US8882735B2 (en) * 2008-12-16 2014-11-11 Kimberly-Clark Worldwide, Inc. Article with fluid-activated barriers
US8507746B2 (en) * 2008-12-16 2013-08-13 Kimberly-Clark Worldwide, Inc. Leakage-signaling absorbent article
US7858055B2 (en) * 2008-12-18 2010-12-28 Kimberly-Clark Worldwide, Inc. Moisture sensitive auxetic material
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
JP5699152B2 (ja) 2009-09-25 2015-04-08 オリゾン・ジェノミックス・ソシエダッド・アノニマOryzon Genomics S.A. リジン特異的デメチラーゼ−1阻害剤およびその使用
EP2486002B1 (de) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituierte heteroaryl- und arylcyclopropylaminacetamide und ihre verwendung
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
US9186337B2 (en) 2010-02-24 2015-11-17 Oryzon Genomics S.A. Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
JP5868948B2 (ja) 2010-04-19 2016-02-24 オリゾン・ジェノミックス・ソシエダッド・アノニマOryzon Genomics S.A. リジン特異的脱メチル化酵素1阻害薬およびその使用
EP2575815A4 (de) 2010-06-04 2013-12-25 Albany Molecular Res Inc Glycin-transporter-1-hemmer, verfahren zu ihrer herstellung und ihre verwendung
WO2012013728A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
JP2013536233A (ja) * 2010-08-23 2013-09-19 アムジエン・インコーポレーテツド グルコキナーゼ調節タンパク質と相互作用する糖尿病治療用の化合物
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
US8708988B2 (en) 2010-12-03 2014-04-29 Kimberly-Clark Worldwide, Inc. Absorbent article configured for controlled deformation
EP2712315B1 (de) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysindemethylase-hemmer für myeloproliferative erkrankungen
AU2012324803B9 (en) 2011-10-20 2017-08-24 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
SG11201401066PA (en) 2011-10-20 2014-10-30 Oryzon Genomics Sa (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
US20160060235A1 (en) * 2013-03-29 2016-03-03 National University Corporation Kumamoto University Therapeutic Agent for Type 2 Diabetes
PE20161573A1 (es) 2014-02-13 2017-01-19 Incyte Corp Ciclopropilamina como inhibidor de la lsd1
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9493450B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
EP3392244A1 (de) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamine als lsd1-inhibitoren
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為lsd1抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
EA039196B1 (ru) * 2014-10-08 2021-12-16 Инсайт Корпорейшн Циклопропиламины в качестве ингибиторов lsd1
PE20180455A1 (es) 2015-04-03 2018-03-05 Incyte Corp Compuestos heterociclicos como inhibidores de lsd1
SG10202001219UA (en) 2015-08-12 2020-03-30 Incyte Corp Salts of an lsd1 inhibitor
CN109414410B (zh) 2016-04-22 2022-08-12 因赛特公司 Lsd1抑制剂的制剂
JP6920411B2 (ja) * 2016-07-25 2021-08-18 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ コリンキナーゼ阻害剤としてのプリン及び3−デアザプリンアナログ
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CN119462614B (zh) * 2025-01-14 2025-05-02 吉林大学 1-mhmd、制备方法及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US3454635A (en) * 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
US4927831A (en) 1988-10-20 1990-05-22 American Home Products Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
PL199236B1 (pl) * 1998-07-08 2008-08-29 Sanofi Aventis Deutschland N-Aryloamidy kwasów sulfonyloaminokarboksylowych podstawionych siarką, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie N-aryloamidów kwasów sulfonyloaminokarboksylowych podstawionych siarką
EP1088815A1 (de) * 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutisch Aktive Sulfonyl-Aminosäurederivate
EP1088821A1 (de) * 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmazeutisch wirksamer Sulfonamid Derivate
EP1193256A1 (de) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmazeutisch aktive Benzolsulfonamidderivate als JNK-Proteininhibitoren
EP1193268A1 (de) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmazeutisch aktive Sulfonamidderivate mit sowohl lipophilen als auch ionisierbaren Gruppen als Inhibitoren von Protein-JunKinasen
EP1193267A1 (de) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmazeutisch wirksame hydrophile Sulfonamidderivate zur Verwendung als Proteinjunkinasehemmer
WO2002100396A1 (en) 2001-06-07 2002-12-19 Wyeth COMBINATION OF A PTPase INHIBITOR AND A THIAZOLIDINEDIONE AGENT
ATE419247T1 (de) * 2001-07-23 2009-01-15 Serono Lab Arylsulfonamidderivate als hemmer c-jun- terminaler kinasen (jnk)
ATE551997T1 (de) 2003-09-12 2012-04-15 Merck Serono Sa Sulfonamid-derivate zur behandlung von diabetes

Also Published As

Publication number Publication date
NO20061598L (no) 2006-06-09
IL174251A0 (en) 2006-08-01
US7705052B2 (en) 2010-04-27
AU2004271741A1 (en) 2005-03-24
JP4870562B2 (ja) 2012-02-08
EP1663193A1 (de) 2006-06-07
ES2385219T3 (es) 2012-07-19
US20070043027A1 (en) 2007-02-22
CA2534312A1 (en) 2005-03-24
EP1663193B1 (de) 2012-04-04
JP2007505088A (ja) 2007-03-08
WO2005025558A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
ATE551997T1 (de) Sulfonamid-derivate zur behandlung von diabetes
EP1873144A4 (de) Kondensierte heterocyclische verbindung
EA200870470A1 (ru) Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1
NO20083480L (no) Piperidinoylpyrrolidiner som melanokortin type 4 reseptor agonister
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
ATE472531T1 (de) Sulfonylverbindungen als hemmer von 11-beta- hydroxysteroiddehydrogenase-1
WO2008155668A3 (en) Heteroarylamide pyrimidone compounds
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
CY1112406T1 (el) Διενυδρη υδροχλωρικη (s)-(-)-1-(4-φθοροϊσοκινολιν-5-υλ)σουλφονυλ-2-μεθυλ-1,4-ομοπιπεραζινη
MX2009012377A (es) Compuestos de arilamida pirimidona.
ATE455772T1 (de) Alkinylarylcarbonsäureamide
WO2008155669A3 (en) Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
ATE431333T1 (de) Amino-propanolderivate
CY1108804T1 (el) Μεθοδος παρασκευης της 4β-αμινο-4'-δεμεθυλ-4- δεσοξυποδοφυλλοτοξινης.
NO20061614L (no) Benzimidazolacetonitriler
CY1113042T1 (el) Αντιμετωπιση μυϊασης
EA200700767A1 (ru) Способ получения пиразолов
DE602004024170D1 (de) Pyrrolidin-derivate als oxytocin antagonisten
RU2014135323A (ru) Соединение, способ получения соединения и способ очистки соединения
MX2007005617A (es) Derivados de vinilaminopirazol como pesticidas.
TH98281A (th) สารประกอบไซคลิกหลอม
BR0316148A (pt) Pirazolinocarboxanilidas substituìdas como composições praguicidas
TH85588B (th) สารไพแรโซโล พิริมิดีน
TH69079A (th) อินโดล-3-คาร์บอกซาไมด์ โดยเป็นตัวกระตุ้นกลูโคไคเนส (gk)
TH102686A (de)